Last reviewed · How we verify
NCT03524963
Comparative Pharmacokinetic Study Between Two Extended-Release Cilostazol Formulations in Korea
Phase 1 trial testing Cilostan CR Tab. in Peripheral Artery Disease in 30 participants. Completed in 30 June 2018.
30 May 2018
Quick facts
| Lead sponsor | Bundang CHA Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 7 August 2017 |
| Primary completion | 30 May 2018 |
| Estimated completion | 30 June 2018 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Cilostan CR Tab. — full drug profile →
- Pletaal SR Cap. — full drug profile →
Conditions studied
- Peripheral Artery Disease — all drugs for Peripheral Artery Disease →
Sponsor
Bundang CHA Hospital
Who can join
Adults 20 to 45, male only, with Peripheral Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, open-label, multiple-dose, two-sequence, two-period crossover study to to compare the safety/tolerability and pharmacokinetics between Pletaal SR Cap. and Cilostan CR Tab. in healthy volunteers
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03524963
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peripheral Artery Disease
Currently open trials in the same condition.
- NCT07374601 — The Value of Super-resolution Ultrasound Imaging for Peripheral Artery Disease · recruiting
- NCT06686121 — Improving Mobility After Revascularization in Peripheral Artery Disease · Phase 3 · recruiting
- NCT04433572 — Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee · Phase 3 · recruiting
- NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
- NCT07012070 — Improving Walking Performance in Patients With Peripheral Artery Disease Through Wearable Activity Trackers · NA · recruiting
Other Bundang CHA Hospital trials
Trials by the same sponsor.
- NCT07366554 — Epigenetic Factors of Colorectal Adenoma in Korean · not yet recruiting
- NCT06982573 — The Effect of Magnetic Stimulation on Low Back Pain Relief and Muscle Mass Maintenance in Patients With ESRD · NA · recruiting
- NCT06982586 — A Prospective, Single-Center, Single-Arm, Investigator-Initiated Exploratory Clinical Trial to Assess the Safety of Repe · NA · not yet recruiting
- NCT06995274 — Umbilical Cord Blood Therapy in a Child With Eosinophilic Duodenitis and Autism Spectrum Disorder: a Case Study · NA · not yet recruiting
- NCT06543797 — A Pilot Clinical Trial Study to Determine the Safety of the Application of a Wearable Medical Electromagnetic Generator · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03524963 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bundang CHA Hospital
- Last refreshed: 24 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03524963.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing